Medicines for Human Use

Pre-authorization evaluation of medicines for human use unit. This unit provides scientific advice relating to quality, safety and efficacy issues, as well as relating to orphan drugs. 

Post-authorization evaluation of medicines for human use. This regulatory affairs unit is responsible for issues such as post-marketing surveillance of drugs. 

The EMEA secretariat comprises four units administration, evaluation of medicines for human use, technical coordination, and evaluation of medicines for veterinary use. 

Significant changes to the legal basis for the exemptions, rather than to their scope, were introduced by the Medicines for Human Use (Marketing Authorisations Etc.) Regulations... 

The rules governing clinical trials in the United Kingdom are now set out in the Medicines for Human Use (Clinical Trials) Regulations 2004, which implement Directive 2001/20/EC on good clinical practice in the conduct of clinical trials. 

A specified party must hold or obtain (and maintain) all necessary authorisations, for example, under the UK Medicines for Human Use (Clinical Trial) Regulations 2004, and sub-ordinate/related legislation, the Data Protection Act 1998 and the Animals (Scientific Procedures) Act 1986. 

The relevant advisory committees with a remit for medicines for human use established under the Medicines Act 1968 were the Committee on Safety of Medicines (CSM), set up in June 1970 (SI 1970/1257) under the Chairmanship of Professor EF Scowen and the British Pharmacopoeia Commission (BPC), also set up in June 1970 (SI 1970/1256) under the Chairmanship of Dr F Hartley (later Sir Frank Hartley). The Veterinary Products Committee (VPC), chaired by Professor CSG Grunsell (with a remit for... 

A new Commission on Human Medicines (CHM) that amalgamates the responsibilities of the present Medicines Commission and the Committee of Safety of Medicines, which will advise Ministers direct on matters relating to medicines for human use. 

CSM in relation to medicines for human use. In particular it would be responsible for ... 

The details of the reform and the large number of legislative changes introduced in relation to medicines for human use are beyond the scope of this chapter. However, the key objectives of the review of EU medicines legislation and reform of the regulatory regime can be summarised as follows ... 

Appointments of rapporteur and co-rapporteur were made on the basis of two criteria first, the preferences expressed by the applicant, and second, the preferences of CHMP members based on their expertise. The CHMP will no longer take into account preferences expressed by applicants in selecting rapporteurs. A member of staff of the Pre-authorisation Evaluation of Medicines for Human Use Unit of the EMEA is officially... 

Committee for Proprietary Medicinal Products Guideline on Comparability of Medicinal Products Containing Biotech-nology-derived Proteins as Active Substance. Non-clinical and Clinical Issues. Evaluation of Medicines for Human Use, The European Agency for the Evaluation ofMedicinal Products, London (2003). 

Guidelines have been established to assist sponsors in the preparation of applications to register new prescription or other high-risk medicines for human use. The format for applications is the Common Technical Document. It is a format that is also used in other parts of the world. 

European Medicines Agency, Evaluation of Medicines for Human Use. Guideline on the Limits of Genotoxic Impurities, EMEA/CHMP/QWP/251344/2006. 

The principal scientific bodies of the EMEA are the CPMP and the Committee for Veterinary Medicinal Products (CVMP). They are made up of two members from each member state as well as from Norway and Iceland, and are appointed to give independent scientific advice to the EMEA. The EMEA Secretariat comprises four units administration, evaluation of medicines for human use, technical coordination, and evaluation of medicines for veterinary use. 

The Unit for the Evaluation of Medicines for Human Use is responsible for the following ... 

In addition, the presentation of monographs has now been supplemented by the establishment of a procedure for Certification of Suitability of Monographs (see later), thus fully satisfying the requirements of Directives 75/318/EEC for medicines for human use and 81/852/EEC for medicines for veterinary use, and the EU note for guidance, Summary of Requirements on Active Substances in Part II of the Dossier. 

Royal Decree of September 16,1985 concerning good practices for experiments with medicines for human use... 

Until the 25th Act of 1998 on medicines for human use came into effect on January 1, 1999, registration and MA were two different legal categories in Hungary. This phenomenon is worth a more detailed explanation. 

The 25th Act of 1998 on medicines for human use (Medicines Act) came into force with the exception of certain parts on January 1,1999. For the most peirt, the Act is in line with the corresponding EU Directives. Its main chapters are as follows. 

---